The goal of this clinical research study is to find the highest tolerable dose of sorafenib (out of 4 possible doses) that can be given in combination with busulfan and fludarabine before an allogeneic stem cell transplant and alone after the transplant. Researchers also want to learn if this combination can help to control acute myeloid leukemia (AML). The safety of this drug combination will also be studied.